[go: up one dir, main page]

EP3386536A4 - Composition of antibody construct-agonist conjugates and methods of use thereof - Google Patents

Composition of antibody construct-agonist conjugates and methods of use thereof Download PDF

Info

Publication number
EP3386536A4
EP3386536A4 EP16873755.9A EP16873755A EP3386536A4 EP 3386536 A4 EP3386536 A4 EP 3386536A4 EP 16873755 A EP16873755 A EP 16873755A EP 3386536 A4 EP3386536 A4 EP 3386536A4
Authority
EP
European Patent Office
Prior art keywords
composition
methods
antibody construct
agonist conjugates
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16873755.9A
Other languages
German (de)
French (fr)
Other versions
EP3386536A2 (en
Inventor
Peter Armstrong Thompson
Badreddin EDRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opi Vi- Ip Holdco LLC
Original Assignee
Opi Vi- Ip Holdco LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/173,075 external-priority patent/US20170158772A1/en
Application filed by Opi Vi- Ip Holdco LLC filed Critical Opi Vi- Ip Holdco LLC
Publication of EP3386536A2 publication Critical patent/EP3386536A2/en
Publication of EP3386536A4 publication Critical patent/EP3386536A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP16873755.9A 2015-12-07 2016-12-07 Composition of antibody construct-agonist conjugates and methods of use thereof Withdrawn EP3386536A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562264260P 2015-12-07 2015-12-07
US15/173,075 US20170158772A1 (en) 2015-12-07 2016-06-03 Compositions of antibody construct - agonist conjugates and methods of use thereof
US201662371141P 2016-08-04 2016-08-04
PCT/US2016/065353 WO2017100305A2 (en) 2015-12-07 2016-12-07 Composition of antibody construct-agonist conjugates and methods of use thereof

Publications (2)

Publication Number Publication Date
EP3386536A2 EP3386536A2 (en) 2018-10-17
EP3386536A4 true EP3386536A4 (en) 2019-07-31

Family

ID=59013332

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16873755.9A Withdrawn EP3386536A4 (en) 2015-12-07 2016-12-07 Composition of antibody construct-agonist conjugates and methods of use thereof

Country Status (4)

Country Link
EP (1) EP3386536A4 (en)
CA (1) CA3007311A1 (en)
DE (1) DE212016000029U1 (en)
WO (1) WO2017100305A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CN108137641B (en) 2015-08-13 2022-04-01 默沙东公司 Cyclic dinucleotide compounds as sting agonists
CN114751950B (en) 2016-03-18 2025-04-18 免疫传感器公司 Cyclic dinucleotide compounds and methods of use
JP7011764B2 (en) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Antibody adjuvant complex
MX386187B (en) 2016-10-04 2025-03-18 Merck Sharp & Dohme Llc BENZOPHEN COMPOUNDS AS STING AGONISTS.
JOP20170192A1 (en) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
EP3576782A4 (en) * 2017-02-02 2020-12-30 Silverback Therapeutics, Inc. CONSTRUCTIVE PEPTIDE COMPOSITIONS AND METHOD OF USING THEREOF
AR113224A1 (en) * 2017-04-28 2020-02-19 Novartis Ag ANTIBODY CONJUGATES INCLUDING A STING AGONIST
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
MA49773A (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO AGONISTS [B
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
CN107365361B (en) * 2017-08-21 2020-05-19 中国药科大学 Repeat domain anchoring protein binding to PD-L1 and its use
EP3676279B1 (en) * 2017-08-31 2021-12-01 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US10947263B2 (en) * 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Compounds compositions, and methods for the treatment of disease
US11707531B2 (en) * 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
CN117586108A (en) * 2017-10-30 2024-02-23 科罗拉多州立大学董事会法人团体 TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof
PE20210156A1 (en) 2017-11-10 2021-01-26 Takeda Pharmaceuticals Co STING MODULATING COMPOUNDS AND METHODS OF PREPARATION AND USE
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
EP3774764A1 (en) 2018-04-03 2021-02-17 Merck Sharp&Dohme Corp. Benzothiophenes and related compounds as sting agonists
EP3774765A4 (en) 2018-04-03 2021-12-29 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
US10947227B2 (en) 2018-05-25 2021-03-16 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
AU2019337051B2 (en) 2018-09-06 2023-11-23 Daiichi Sankyo Company, Limited Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
AU2020267486A1 (en) 2019-05-09 2021-11-11 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as STING modulators
SG11202112223XA (en) * 2019-05-10 2021-12-30 Takeda Pharmaceuticals Co Antibody drug conjugates
CA3144533A1 (en) * 2019-06-03 2020-12-10 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
WO2020245321A1 (en) 2019-06-04 2020-12-10 Institut Curie METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
KR20220054794A (en) 2019-07-19 2022-05-03 이뮨센서 테라퓨틱스, 인코포레이티드 Antibody-STING agonist conjugates and their use in immunotherapy
KR20220056176A (en) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 Bis-[N-((5-carbamoyl)-1H-benzo[D]imidazol-2-yl)-pyrazole-5-carboxamide] as STING (stimulator of interferon gene) agonist for cancer treatment Derivatives and related compounds
CN114630684A (en) * 2019-09-03 2022-06-14 博尔特生物治疗药物有限公司 Aminoquinoline compounds, immunoconjugates and uses thereof
BR112022010680A2 (en) 2019-12-03 2022-08-16 Evotec Int Gmbh ANTIGEN-BINDING PROTEINS ASSOCIATED WITH INTERFERON AND THEIR USE
WO2021110987A1 (en) 2019-12-06 2021-06-10 Life & Soft Methods and apparatuses for diagnosing cancer from cell-free nucleic acids
CN111233850B (en) * 2020-01-21 2022-09-23 南开大学 Naphthol derivative containing benzothiazole amino and heteroaryl and preparation method and application thereof
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
KR20220151630A (en) 2020-03-06 2022-11-15 다이이찌 산쿄 가부시키가이샤 Antibody Drug Conjugates Containing Novel Cyclic Dinucleotide Derivatives
ES3007532T3 (en) 2020-03-13 2025-03-20 Hephaistos Pharma Detoxified lipopolysaccharides (lps), naturally non-toxic lps, and uses thereof
EP4218826A3 (en) 2020-04-02 2023-10-25 Mersana Therapeutics, Inc. Antibody drug conjugates comprising sting agonists
EP4149457A1 (en) 2020-05-15 2023-03-22 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with immune checkpoint inhibitors
TW202216211A (en) 2020-07-01 2022-05-01 美商希沃爾拜克治療公司 Anti-asgr1 antibody conjugates and uses thereof
EP3943505A1 (en) 2020-07-22 2022-01-26 Encefa Cd38-binding cd31 peptides and uses thereof
US20240336907A1 (en) 2020-09-02 2024-10-10 Daiichi Sankyo Company, Limited NOVEL ENDO-ß-N-ACETYLGLUCOSAMINIDASE
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
US20240033366A1 (en) 2020-12-02 2024-02-01 Institut Curie FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF
CN117320732A (en) 2021-02-26 2023-12-29 屏蔽药房 Non-autologous polystress cancer cells for cancer vaccination and therapy and their applications
AU2022315305A1 (en) 2021-07-23 2024-02-01 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
CN118369344A (en) 2021-09-16 2024-07-19 阿博莱斯制药公司 Anti-human CD45RC binding domain and its use
US20250108123A1 (en) * 2021-12-17 2025-04-03 Jacobio Pharmaceuticals Co., Ltd. Compound-linker constructs comprising novel compounds useful as sting agonists and uses thereof
KR20240155298A (en) 2022-03-02 2024-10-28 다이이찌 산쿄 가부시키가이샤 Method for producing Fc-containing molecules
EP4582106A1 (en) 2022-08-29 2025-07-09 Daiichi Sankyo Company, Limited Antibody-drug conjugate including mutant fc region
WO2024193253A1 (en) * 2023-03-18 2024-09-26 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Anti-her3/muc1 antibodies and uses thereof
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103987A1 (en) * 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating her2 positive tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920561A1 (en) * 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for thrombin and methods of use
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (en) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 Deuterated compound and composition for treating hypertension
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
EP2844282B1 (en) * 2012-05-04 2019-06-12 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103987A1 (en) * 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating her2 positive tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADAM J. R. GADD ET AL: "Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity", BIOCONJUGATE CHEMISTRY, vol. 26, no. 8, 16 July 2015 (2015-07-16), US, pages 1743 - 1752, XP055455345, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00302 *
SINGH S.K., LUISI D.L. & PAK R.H.: "Antibody-Drug Conjugates: Design, Formulationand Physicochemical Stability", PHARM. RES., vol. 32, 19 May 2015 (2015-05-19), pages 3541 - 3571, XP002792278 *

Also Published As

Publication number Publication date
EP3386536A2 (en) 2018-10-17
WO2017100305A3 (en) 2017-07-20
CA3007311A1 (en) 2017-06-15
WO2017100305A2 (en) 2017-06-15
WO2017100305A8 (en) 2017-09-08
DE212016000029U1 (en) 2017-07-30

Similar Documents

Publication Publication Date Title
EP3386536A4 (en) Composition of antibody construct-agonist conjugates and methods of use thereof
EP3353210B8 (en) Anti-tigit antibodies and methods of use
EP3337517A4 (en) Anti-dll3 antibody drug conjugates and methods of use
EP3280441A4 (en) Anti-sortilin antibodies and methods of use thereof
EP3151830A4 (en) Anti-her2 antibody-maytansine conjugates and methods of use thereof
EP3177322A4 (en) Anti-trem2 antibodies and methods of use thereof
EP3248005A4 (en) Novel glycan conjugates and methods of use thereof
EP3559042A4 (en) Anti-lilrb3 antibodies and methods of use thereof
EP3283493A4 (en) Texaphyrin-phospholipid conjugates and methods of preparing same
AU2017271189A1 (en) Cytosol-penetrating antibody and use thereof
EP3448885A4 (en) Antibody conjugates and methods of making and using the same
EP3288542A4 (en) Compositions and methods for administering antibodies
EP3454864A4 (en) Novel anti-bmpr1b antibodies and methods of use
EP3239177A4 (en) Novel egfrviii antibody and composition comprising same
GB201620828D0 (en) Compositions of antibody construct-agonist conjugates and methods thereof
HK40103259A (en) Anti-trem2 antibodies and methods of use thereof
HK40087685A (en) Anti-siglec-9 antibodies and methods of use thereof
HK1261040A1 (en) Composition of antibody construct-agonist conjugates and methods of use thereof
HK40114293A (en) Antibodies and methods of use thereof
HK40113626A (en) Anti-tim-3 antibodies and methods of use thereof
HK40109868A (en) Anti-sirp-alpha antibodies and methods of use thereof
HK40109063A (en) Anti-lag-3 antibodies and methods of use thereof
HK40097160A (en) Anti-tim-3 antibodies and use thereof
HK40088438A (en) Anti-tim-3 antibodies and use thereof
HK40110799A (en) Antibodies for siglec-15 and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180706

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190701

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/32 20060101ALI20190624BHEP

Ipc: A61K 39/395 20060101ALI20190624BHEP

Ipc: A61K 39/39 20060101ALI20190624BHEP

Ipc: C07K 16/28 20060101ALI20190624BHEP

Ipc: A61K 47/68 20170101ALI20190624BHEP

Ipc: A61K 39/00 20060101AFI20190624BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261040

Country of ref document: HK

17Q First examination report despatched

Effective date: 20200213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200624